Onconova Therapeutics develops novel cancer treatments in the US. Two clinical-stage programs include narazaciclib for solid tumors and hematological malignancies, and oral rigosertib for progressive K-Ras mutated non-small cell lung cancer. Rigosertib is also being tested as a monotherapy for advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. The company has a license agreement for narazaciclib in China. Onconova was founded in 1998 and is headquartered in Pennsylvania.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 2.0 |